Pacira Pharmaceuticals buy StockNews.com
Start price
05.08.23
/
50%
€35.80
Target price
05.08.24
-
Performance (%)
-46.93%
End price
06.08.24
€19.00
Summary
This prediction ended on 06.08.24 with a price of €19.00. The BUY prediction by StockNews_com for Pacira Pharmaceuticals performed very badly with a performance of -46.93%. StockNews_com has a follow-up prediction for Pacira Pharmaceuticals where he still thinks Pacira Pharmaceuticals is a Buy. StockNews_com has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Pacira Pharmaceuticals | -6.604% | -6.604% | -5.714% | -40.361% |
| iShares Core DAX® | 0.437% | 5.897% | 8.047% | 65.579% |
| iShares Nasdaq 100 | 1.057% | 0.920% | 28.466% | 90.185% |
| iShares Nikkei 225® | 1.769% | 1.228% | 47.574% | 84.991% |
| iShares S&P 500 | 0.368% | 1.920% | 23.200% | 70.760% |
Comments by StockNews_com for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for PCRX provided by MarketBeat
In the thread Trading Pacira Pharmaceuticals
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten